December 19th 2019
Everett E. Vokes, MD, FASCO, who is a Giants of Cancer Care® recipient for Head and Neck Cancer, has been named the next president of ASCO for the 2021 to 2022 term.
The FDA has granted a priority review designation to a new drug application for UGN-101 for the treatment of patients with low-grade, upper tract urothelial cancer.
A new drug application has been submitted to the FDA for tazemetostat as a treatment for patients with relapsed/refractory follicular lymphoma, with or without EZH2 activating mutations, who have received ≥2 prior lines of systemic therapy.
The FDA has granted a priority review designation to a supplemental new drug application for the combination of encorafenib and cetuximab as a treatment for patients with advanced BRAF V600E–mutant metastatic colorectal cancer following up to 2 prior lines of therapy.
December 18th 2019
The FDA’s Oncologic Drugs Advisory Committee voted in favor of approving tazemetostat tablets as a treatment for patients with metastatic or locally advanced epithelioid sarcoma that is ineligible for curative surgery.
The FDA has granted a breakthrough therapy designation to ivosidenib for the treatment of adult patients with relapsed/refractory myelodysplastic syndromes who harbor IDH1 mutations.
December 17th 2019
The FDA’s Oncologic Drugs Advisory Committee voted 7 to 5 in favor of olaparib tablets for an indication as a maintenance treatment of adult patients with deleterious or suspected deleterious BRCA-mutant metastatic pancreatic adenocarcinoma whose disease has not progressed on frontline platinum-based chemotherapy.
The FDA has approved a supplemental new drug application for enzalutamide (Xtandi) for the treatment of patients with metastatic castration-sensitive prostate cancer.
Zanubrutinib did not show a statistically significant improvement in complete response and very good partial response rates compared with ibrutinib in patients with Waldenström macroglobulinemia, missing the primary endpoint of the phase III ASPEN trial.
December 16th 2019
A new drug application has been submitted to the FDA for ripretinib for use as a treatment for patients with advanced gastrointestinal stromal tumors who have previously received treatment with imatinib, sunitinib, and regorafenib.
Treatment with entrectinib led to an overall response rate of 77% and a median duration of response of 24.6 months in patients with ROS1 fusion–positive non–small cell lung cancer, according to updated findings of a pooled analysis published in Lancet Oncology.
December 14th 2019
The presence of circulating tumor DNA and circulating tumor cells following neoadjuvant chemotherapy can be an independent predictor of disease recurrence in patients with early triple-negative breast cancer.
December 13th 2019
The triplet regimen of atezolizumab, cobimetinib, and vemurafenib was found to improve progression-free survival compared with cobimetinib/vemurafenib plus placebo in patients with previously untreated BRAF V600 mutation–positive advanced melanoma.
Atezolizumab (Tecentriq) in combination with carboplatin and nab-paclitaxel (Abraxane) did not lead to a statistically significant increase in pathologic complete response (pCR) rate compared with carboplatin/nab-paclitaxel alone in patients with early high-risk and locally advanced triple-negative breast cancer,
A biologics license application has been submitted to the FDA for the investigational CAR T-cell therapy KTE-X19 as a treatment for adult patients with relapsed/refractory mantle cell lymphoma.
December 12th 2019
Adjuvant pertuzumab (Perjeta) with trastuzumab (Herceptin) plus chemotherapy showed a 0.9% improvement in overall survival and continued to reduce the risk of disease recurrence in patients with HER2-positive early breast cancer.
December 10th 2019
The CAR T-cell therapy tisagenlecleucel (Kymriah) showed similar real-world efficacy and safety findings to that of the JULIET trial in the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma.
Blinatumomab (Blincyto) as post-reinduction consolidation therapy before hematopoietic stem cell transplantation improved disease-free survival and overall survival by approximately 20% compared with intensive chemotherapy in pediatric and adolescent and young adult patients with high- or intermediate-risk of first relapse of B-cell acute lymphoblastic leukemia.
December 9th 2019
The combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) elicited a 100% overall response rate in patients with relapsed indolent non-Hodgkin lymphoma that was refractory to rituximab (Rituxan).
The combination of lenalidomide (Revlimid) and rituximab showed a 34% reduction in the risk of disease progression or death compared with rituximab plus placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma, although it was not found to be statistically significant.